Søren M. Bentzen

ORCID: 0000-0002-7444-7564
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advanced Radiotherapy Techniques
  • Effects of Radiation Exposure
  • Head and Neck Cancer Studies
  • Radiomics and Machine Learning in Medical Imaging
  • Radiation Therapy and Dosimetry
  • Lung Cancer Diagnosis and Treatment
  • Medical Imaging Techniques and Applications
  • Lung Cancer Treatments and Mutations
  • Breast Cancer Treatment Studies
  • Radiation Dose and Imaging
  • Prostate Cancer Diagnosis and Treatment
  • Advances in Oncology and Radiotherapy
  • Glioma Diagnosis and Treatment
  • Prostate Cancer Treatment and Research
  • Brain Metastases and Treatment
  • Lung Cancer Research Studies
  • Endometrial and Cervical Cancer Treatments
  • Management of metastatic bone disease
  • Acute Myeloid Leukemia Research
  • Ultrasound and Hyperthermia Applications
  • Lymphoma Diagnosis and Treatment
  • Cancer Diagnosis and Treatment
  • Global Cancer Incidence and Screening
  • Cancer Genomics and Diagnostics
  • Cervical Cancer and HPV Research

University of Maryland, Baltimore
2016-2025

U-M Rogel Cancer Center
2016-2025

University of Mary
2016-2025

University of Maryland Medical Center
2019-2025

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2015-2024

Ministry of Health and Population
2024

University Hospitals of Cleveland
2024

University of Baltimore
2017-2024

Assistance Publique – Hôpitaux de Paris
2021

Rigshospitalet
2010-2021

To determine the protective effects of memantine on cognitive function in patients receiving whole-brain radiotherapy (WBRT).Adult with brain metastases received WBRT and were randomized to receive placebo or (20 mg/d), within 3 days initiating for 24 weeks. Serial standardized tests performed.Of 554 who accrued, 508 eligible. Grade 4 toxicities study compliance similar 2 arms. There was less decline delayed recall arm at weeks (P = .059), but difference not statistically significant,...

10.1093/neuonc/not114 article EN Neuro-Oncology 2013-08-16
Richard Pötter Kari Tanderup Maximilian Schmid Ina M. Jürgenliemk‐Schulz Christine Haie-Méder and 87 more Lars Fokdal Alina Sturdza Peter Hoskin Umesh Mahantshetty Barbara Šegedin Kjersti Bruheim Fleur Huang Bhavana Rai Rachel Cooper Elzbieta van der Steen-Banasik Erik Van Limbergen Bradley R. Pieters Li Tee Tan Remi A. Nout Astrid A.C. de Leeuw Robin Ristl Primož Petrič N. Nesvacil Kathrin Kirchheiner Christian Kirisits Jacob Christian Lindegaard Cyrus Chargari Isabelle Dumas Gerry Lowe Jamema Swamidas Robert Hudej Taran Paulsen Hellebust Geetha Menon Arun S. Oinam Peter Bownes Melissa Christiaens Marisol De Brabandere Hilde Janssen B.J. Oosterveld Kees Koedooder Anne Beate Langeland Marthinsen Marit Sundset Diane Whitney Martijn Ketelaars Ludy Lutgens Brigitte Reinniers Itxa Mora E. Villafranca Gergely Antal Janaki Hadjiev François Bachand Deidre Batchelar Bradley A. Erickson Jason Rownd G. Jacobson Yusung Kim Maarit Anttila Jan-Erik Palmgren Jusheng An Marianne S. Assenholt Susovan Banerjee Søren M. Bentzen Thomas Berger Pittaya Dankulchai Tamara Diendorfer Ian Dilworth Johannes Dimopoulos E. Dörr Stefan Ecker Mario Federico Elena Fidarova Israël Fortin Petra Georg Joanna Góra Neamat Hegazy Noha Jastaniyah Nina Boje Kibsgaard Jensen Thomas Liederer Katarina Majerčáková Dragan Misimovic Laura Motisi D. Najjari Jamal Karen Nkiwane Anders Schwartz-Vittrup Monica Serban Stéphanie Smet Sofia Spampinato Petra Trnková Margit Valgma Henrike Westerveld Joyce Siu Yu Wong Kenji Yoshida

10.1016/s1470-2045(20)30753-1 article EN The Lancet Oncology 2021-03-29

PURPOSE This study attempted to determine the efficacy of combination etoposide (VP-16), methyl-prednisolone, and cytarabine (Ara-C) with or without cisplatin in relapsing refractory adult lymphoma patients. PATIENTS AND METHODS The first 63 patients were randomized receive VP-16 40 mg/m2/d for 4 days, methylprednisolone 500 mg intravenously daily 5 Ara-C 2 g/m2 over 3 hours on day 25 mg/m2 IV administered by 24-hour infusion days (ESHA +/- P). Markedly different responses between ESHA (33%)...

10.1200/jco.1994.12.6.1169 article EN Journal of Clinical Oncology 1994-06-01

Purpose Brain metastasis (BM) is a major cause of suffering and health costs in cancer patients. Whole-brain radiation therapy (WBRT) offers tumor shrinking palliation many cases, but it has been speculated that these benefits may be outweighed by adverse effects on neurocognitive function (NCF). Patients Methods Two hundred eight BM patients from the WBRT arm phase III trial PCI-P120-9801 evaluating motexafin gadolinium were analyzed. NCF, assessed tests memory, executive function, fine...

10.1200/jco.2006.09.2536 article EN Journal of Clinical Oncology 2007-03-30

Phase II clinical studies suggest that hypoxic modification with carbogen and nicotinamide (CON) may increase the efficacy of radiotherapy (RT).Three hundred thirty-three patients locally advanced bladder carcinoma were randomly assigned to RT alone versus CON. A schedule either 55 Gy in 20 fractions 4 weeks or 64 32 6.5 was used. The primary end point cystoscopic control at 6 months (CC(6m)) secondary points overall survival (OS), local relapse-free (RFS), urinary rectal morbidity.CC(6m)...

10.1200/jco.2010.28.4950 article EN Journal of Clinical Oncology 2010-10-19

Several studies have reported associations between radiation toxicity and single nucleotide polymorphisms (SNPs) in candidate genes. Few been tested independent validation studies. This prospective study aimed to validate genotype a large dataset.92 (of 98 attempted) SNPs 46 genes were successfully genotyped 1613 patients: 976 received adjuvant breast radiotherapy the Cambridge IMRT trial (ISRCTN21474421, n=942) or of at Christie Hospital, Manchester, UK (n=34). A further 637 radical...

10.1016/s1470-2045(11)70302-3 article EN cc-by The Lancet Oncology 2011-12-13
Coming Soon ...